News Bayer starts pivotal Parkinson's cell therapy trial Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway.
News ESC: MSD/Bayer's Verquvo disappoints in heart failure trial Bayer and MSD's hopes of expanding the use of Verquvo in heart failure have been dashed by a failed phase 3 trial.
News Bayer files 'safer, greener' MRI contrast agent in US FDA starts its review of Bayer's gadoquatrane, an MRI contrast agent that reduces the amount of gadolinium in medical imaging procedures.
News Bayer buys into KRAS with $1.3bn Kumquat deal Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer, via an alliance with San Diego biotech Kumquat.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
